Replies to post #2676 on Ocera Therapeutics fka OCRX

[north40000]

More exciting is the pre-market increase in share price,so far.

[north40000]

Agree if you mean acquisition by MNK for $1.52/share--MNK has had its own share of controversy of late. Is market anticipating a bidding war? I would think GILD, with its focus on hepatic disease in general, would be interested in OCRX.

http://ih.advfn.com/p.php?pid=nmona&article=75999661

We did not attend the Liver-related convention here in Washington many days ago for OCRX presentations.